Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Irritable Bowel Syndrome (IBS) Treatment Market

Irritable Bowel Syndrome (IBS) Treatment Market Size, Share & Trends Analysis Report, By IBS Type (IBS-C, IBS-D, IBS-M, IBS-U), By Drug Class (Laxatives, Antidiarrheal Agents, Antispasmodics, Antibiotics, Serotonin Receptor Modulators, GC-C Agonists, Chloride Channel Activators, Antidepressants, Bile Acid Sequestrants), By End User (Hospitals, Specialty Gastroenterology Clinics, Homecare Settings), Forecast Period (2026-2035)

Published: Jun 2026 | Report Code: OMR2029744 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Irritable Bowel Syndrome (IBS) treatment market was valued at $12.4 billion in 2025 and is projected to reach $20.5 billion by 2035, expanding at a CAGR of 5.2% from 2026 to 2035. The market growth is primarily driven by the rising global prevalence of gastrointestinal disorders and increasing demand for targeted pharmacological therapies. According to the World Health Organization (WHO), functional gastrointestinal disorders, including IBS, affect approximately 10–15% of the global population, making it one of the most prevalent chronic digestive conditions. Additionally, data from the Organisation for Economic Co-operation and Development (OECD) indicates that healthcare spending accounts for nearly 9–12% of GDP across developed economies, highlighting increased investment in chronic disease management and gastrointestinal care. The expansion of healthcare infrastructure, rising awareness of IBS symptoms, and growing adoption of advanced therapies such as GC-C agonists and serotonin modulators are further accelerating market growth. Major end-use sectors, including hospitals, specialty gastroenterology clinics, and homecare settings, are witnessing increased patient inflow and treatment demand, contributing significantly to revenue generation.

Market Dynamics

Rising Global Burden of Gastrointestinal Disorders Driving Market Growth

The increasing prevalence of gastrointestinal disorders is a major driver for the IBS treatment market. According to the WHO, digestive diseases contribute significantly to global morbidity, with IBS affecting millions of individuals worldwide. Furthermore, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights growing investments in gastrointestinal drug development, supporting innovation in targeted therapies.

Lifestyle factors such as unhealthy diets, high stress levels, and sedentary habits are contributing to the increasing incidence of IBS globally. Additionally, the U.S. Food and Drug Administration (FDA) has approved several IBS-specific therapies in recent years, reflecting strong regulatory support and increasing treatment availability. Pharmaceutical companies are actively expanding their product portfolios through strategic collaborations and product launches. Between 2025 and 2026, companies have focused on expanding access to IBS therapies across emerging markets, improving affordability and penetration. These developments are expected to significantly drive demand across hospitals and specialty clinics.

High Treatment Costs and Limited Curative Therapies

Despite strong growth prospects, the IBS treatment market faces several challenges, including high treatment costs and the absence of definitive curative therapies. IBS management primarily focuses on symptom relief, requiring long-term treatment, which increases healthcare costs for patients. According to the OECD, out-of-pocket healthcare expenditure remains high in several regions, limiting access to advanced IBS therapies. Additionally, variability in patient response to treatment complicates drug development and reduces treatment efficacy rates. Supply chain disruptions and pricing pressures for branded drugs also impact market growth. Pharmaceutical companies are increasingly investing in generic drug development and biosimilar alternatives to address cost concerns. Innovation in microbiome-based therapies and personalized medicine is emerging as a potential solution to overcome these limitations, although widespread adoption remains in early stages.

Market Segmentation

  • Based on the IBS Type, the market is segmented into IBS with Constipation (IBS-C), IBS with Diarrhea (IBS-D), Mixed IBS (IBS-M), and Unsubtyped IBS (IBS-U).
  • Based on the Drug Class, the market is segmented into Laxatives, Antidiarrheal Agents, Antispasmodics, Antibiotics, Serotonin Receptor Modulators, Guanylate Cyclase-C Agonists, Chloride Channel Activators, Antidepressants, and Bile Acid Sequestrants.
  • Based on the End User, the market is segmented into Hospitals, Specialty Gastroenterology Clinics, and Homecare Settings.

IBS with Constipation (IBS-C) Segment Leads the Market

The IBS-C segment dominates the global IBS treatment market due to its higher diagnosis rates and strong demand for targeted therapies. Patients with IBS-C often require long-term treatment, leading to sustained demand for drugs such as GC-C agonists and chloride channel activators.

Pharmaceutical companies have heavily invested in IBS-C therapies between 2022 and 2026, with increased approvals and expanded indications. The growing availability of advanced drugs such as linaclotide and tenapanor has significantly improved treatment outcomes, driving adoption across hospitals and specialty clinics.

Guanylate Cyclase-C (GC-C) Agonists Segment to Record Strong Growth

The GC-C agonists segment is expected to register the fastest growth during the forecast period due to its targeted mechanism of action and superior clinical efficacy. These drugs improve intestinal fluid secretion and reduce abdominal pain, offering better symptom management compared to traditional therapies.

Increasing investment in research and development, along with regulatory approvals, is accelerating the adoption of GC-C agonists globally. Pharmaceutical companies are focusing on expanding production capacity and geographic reach to capitalize on growing demand.

Regional Outlook

The global irritable bowel syndrome (IBS) treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the IBS treatment market due to advanced healthcare infrastructure and high diagnosis rates. According to the U.S. FDA, the country has witnessed a steady increase in approvals for gastrointestinal therapies, supporting market growth. Additionally, the OECD reports high healthcare spending levels, exceeding $12,000 per capita, enabling access to advanced treatments. Strong presence of major pharmaceutical companies and robust reimbursement systems further contribute to market dominance.

China to Record Strong Growth

China is expected to witness significant growth due to expanding healthcare infrastructure and increasing awareness of gastrointestinal diseases. According to the WHO, rising urbanization and dietary changes are contributing to higher incidence of digestive disorders in Asia-Pacific. Additionally, data from the UN Comtrade Database highlights increasing pharmaceutical trade and imports, supporting market expansion. Government initiatives to improve healthcare access and domestic pharmaceutical manufacturing are further driving growth.

Competitive Landscape

The IBS treatment market is characterized by moderate competition, with a mix of global pharmaceutical companies and regional players. Companies are focusing on innovation, product differentiation, and strategic collaborations to strengthen their market position. Leading players such as AbbVie Inc., Ironwood Pharmaceuticals, Takeda Pharmaceutical Company, Bausch Health Companies Inc., and Allergan (AbbVie) dominate the market through strong product portfolios and global distribution networks. Continuous investment in R&D and pipeline development remains a key strategy for sustaining competitive advantage.

Recent Developments

  • In January 2025, ANI Pharmaceuticals launched generic Prucalopride tablets (reference: Motegrity) following approval from the U.S. Food and Drug Administration, expanding access to treatments for chronic constipation and supporting the broader gastrointestinal therapeutics market.
  • In March 2026, Ardelyx published new clinical analysis data demonstrating that Tenapanor (IBSRELA) provides rapid and sustained symptom relief in patients with IBS-C, supporting its clinical efficacy and strengthening its position in the IBS treatment market.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global irritable bowel syndrome (IBS) treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Irritable Bowel Syndrome (IBS) Treatment Market Sales Analysis – IBS Type | Drug Class | End User ($ Million)
  • Irritable Bowel Syndrome (IBS) Treatment Market Sales Performance of Top Countries

 1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

 1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Irritable Bowel Syndrome (IBS) Treatment Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Irritable Bowel Syndrome (IBS) Treatment Market

2.3.1 Competitive Rivalry

2.3.2 Threat of New Entrants

2.3.3 Bargaining Power of Suppliers

2.3.4 Bargaining Power of Buyers

2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Irritable Bowel Syndrome (IBS) Treatment Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Irritable Bowel Syndrome (IBS) Treatment Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Irritable Bowel Syndrome (IBS) Treatment Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Irritable Bowel Syndrome (IBS) Treatment Market Revenue and Share by Manufacturers

  • Irritable Bowel Syndrome (IBS) Treatment Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 AbbVie Inc.

4.2.1.1 Overview

4.2.1.2 Product Portfolio

4.2.1.3 Financial Analysis

4.2.1.4 SWOT Analysis

4.2.1.5 Business Strategy

4.2.2 Ironwood Pharmaceuticals

4.2.2.1 Overview

4.2.2.2 Product Portfolio

4.2.2.3 Financial Analysis

4.2.2.4 SWOT Analysis

4.2.2.5 Business Strategy

4.2.3 Takeda Pharmaceutical Company

4.2.3.1 Overview

4.2.3.2 Product Portfolio

4.2.3.3 Financial Analysis

4.2.3.4 SWOT Analysis

4.2.3.5 Business Strategy

4.2.4 Bausch Health Companies Inc.

4.2.4.1 Overview

4.2.4.2 Product Portfolio

4.2.4.3 Financial Analysis

4.2.4.4 SWOT Analysis

4.2.4.5 Business Strategy

4.2.5 Allergan (AbbVie)

4.2.5.1 Overview

4.2.5.2 Product Portfolio

4.2.5.3 Financial Analysis

4.2.5.4 SWOT Analysis

4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition

4.3.2 Product Launch

4.3.3 Partnership And Collaboration

  1. 5. Global Irritable Bowel Syndrome (IBS) Treatment Market Sales Analysis by IBS Type ($ Million)

5.1 IBS with Constipation (IBS-C)

5.2 IBS with Diarrhea (IBS-D)

5.3 Mixed IBS (IBS-M)

5.4 Unsubtyped IBS (IBS-U)

  1. Global Irritable Bowel Syndrome (IBS) Treatment Market Sales Analysis by Drug Class ($ Million)

6.1 Laxatives

6.2 Antidiarrheal Agents

6.3 Antispasmodics

6.4 Antibiotics

6.5 Serotonin Receptor Modulators

6.6 Guanylate Cyclase-C Agonists

6.7 Chloride Channel Activators

6.8 Antidepressants

6.9 Bile Acid Sequestrants

  1. Global Irritable Bowel Syndrome (IBS) Treatment Market Sales Analysis by End User ($ Million)

7.1 Hospitals

7.2 Specialty Gastroenterology Clinics

7.3 Homecare Settings

  1. Regional Analysis

8.1 North American Irritable Bowel Syndrome (IBS) Treatment Market Sales Analysis – IBS Type | Drug Class | End User ($ Million)

8.1.1 United States

8.1.2 Canada

8.2 European Irritable Bowel Syndrome (IBS) Treatment Market Sales Analysis – IBS Type | Drug Class | End User ($ Million)

8.2.1 UK

8.2.2 Germany

8.2.3 Italy

8.2.4 Spain

8.2.5 France

8.2.6 Russia

8.2.7 Rest of Europe

 

8.3 Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market Sales Analysis – IBS Type | Drug Class | End User ($ Million)

8.3.1 China

8.3.2 Japan

8.3.3 South Korea

8.3.4 India

8.3.5 Australia & New Zealand

8.3.6 ASEAN Countries

8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Irritable Bowel Syndrome (IBS) Treatment Market Sales Analysis – IBS Type | Drug Class | End User ($ Million)

8.4.1 Latin America

8.4.2 Middle East and Africa

  1. Company Profiles

9.1 Abbott Laboratories

9.1.1 Quick Facts

9.1.2 Company Overview

9.1.3 Product Portfolio

9.1.4 Business Strategies

9.2 Alfasigma S.p.A.

9.2.1 Quick Facts

9.2.2 Company Overview

9.2.3 Product Portfolio

9.2.4 Business Strategies

9.3 Ardelyx Inc.

9.3.1 Quick Facts

9.3.2 Company Overview

9.3.3 Product Portfolio

9.3.4 Business Strategies

9.4 Astellas Pharma Inc.

9.4.1 Quick Facts

9.4.2 Company Overview

9.4.3 Product Portfolio

9.4.4 Business Strategies

9.5 Bayer AG

9.5.1 Quick Facts

9.5.2 Company Overview

9.5.3 Product Portfolio

9.5.4 Business Strategies

9.6 Dr. Reddy’s Laboratories Ltd.

9.6.1 Quick Facts

9.6.2 Company Overview

9.6.3 Product Portfolio

9.6.4 Business Strategies

9.7 GlaxoSmithKline plc

9.7.1 Quick Facts

9.7.2 Company Overview

9.7.3 Product Portfolio

9.7.4 Business Strategies

9.8 Ipsen Pharma

9.8.1 Quick Facts

9.8.2 Company Overview

9.8.3 Product Portfolio

9.8.4 Business Strategies

9.9 Johnson & Johnson

9.9.1 Quick Facts

9.9.2 Company Overview

9.9.3 Product Portfolio

9.9.4 Business Strategies

9.10 Menarini Group

9.10.1 Quick Facts

9.10.2 Company Overview

9.10.3 Product Portfolio

9.10.4 Business Strategies

9.11 Novartis AG

9.11.1 Quick Facts

9.11.2 Company Overview

9.11.3 Product Portfolio

9.11.4 Business Strategies

9.12 Pfizer Inc.

9.12.1 Quick Facts

9.12.2 Company Overview

9.12.3 Product Portfolio

9.12.4 Business Strategies

9.13 Procter & Gamble

9.13.1 Quick Facts

9.13.2 Company Overview

9.13.3 Product Portfolio

9.13.4 Business Strategies

9.14 Reckitt Benckiser

9.14.1 Quick Facts

9.14.2 Company Overview

9.14.3 Product Portfolio

9.14.4 Business Strategies

9.15 Sanofi

9.15.1 Quick Facts

9.15.2 Company Overview

9.15.3 Product Portfolio

9.15.4 Business Strategies

9.16 Sun Pharmaceutical Industries Ltd.

9.16.1 Quick Facts

9.16.2 Company Overview

9.16.3 Product Portfolio

9.16.4 Business Strategies

9.17 Synergy Pharmaceuticals (Bausch Health)

9.17.1 Quick Facts

9.17.2 Company Overview

9.17.3 Product Portfolio

9.17.4 Business Strategies                                                     

9.18 Teva Pharmaceutical Industries Ltd.

9.18.1 Quick Facts

9.18.2 Company Overview

9.18.3 Product Portfolio

9.18.4 Business Strategies

9.19 Viatris Inc.

9.19.1 Quick Facts

9.19.2 Company Overview

9.19.3 Product Portfolio

9.19.4 Business Strategies

9.20 Zydus Lifesciences Ltd.

9.20.1 Quick Facts

9.20.2 Company Overview

9.20.3 Product Portfolio

9.20.4 Business Strategies

1. Global Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by IBS Type, 2025–2035 ($ Million) 

2. Global IBS with Constipation (IBS-C) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

3. Global IBS with Diarrhea (IBS-D) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

4. Global Mixed IBS (IBS-M) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

5. Global Unsubtyped IBS (IBS-U) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

6. Global Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million) 

7. Global Laxatives Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

8. Global Antidiarrheal Agents Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

9. Global Antispasmodics Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

10. Global Antibiotics Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

11. Global Serotonin Receptor Modulators Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

12. Global Guanylate Cyclase-C Agonists Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

13. Global Chloride Channel Activators Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

14. Global Antidepressants Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

15. Global Bile Acid Sequestrants Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

16. Global Irritable Bowel Syndrome IBS Treatment for Hospitals Market Research and Analysis by Region, 2025–2035 ($ Million) 

17. Global Irritable Bowel Syndrome IBS Treatment for Specialty Gastroenterology Clinics Market Research and Analysis by Region, 2025–2035 ($ Million) 

18. Global Irritable Bowel Syndrome IBS Treatment for Homecare Settings Market Research and Analysis by Region, 2025–2035 ($ Million) 

19. Global Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

20. North America Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Country, 2025–2035 ($ Million) 

21. North America Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by IBS Type, 2025–2035 ($ Million) 

22. North America Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million) 

23. North America Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by End User, 2025–2035 ($ Million) 

24. Europe Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Country, 2025–2035 ($ Million) 

25. Europe Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by IBS Type, 2025–2035 ($ Million) 

26. Europe Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million) 

27. Europe Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by End User, 2025–2035 ($ Million) 

28. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Country, 2025–2035 ($ Million) 

29. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by IBS Type, 2025–2035 ($ Million) 

30. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million) 

31. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by End User, 2025–2035 ($ Million) 

32. Rest of the World Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Region, 2025–2035 ($ Million) 

33. Rest of the World Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by IBS Type, 2025–2035 ($ Million) 

34. Rest of the World Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by Drug Class, 2025–2035 ($ Million) 

35. Rest of the World Irritable Bowel Syndrome (IBS) Treatment Market Research and Analysis by End User, 2025–2035 ($ Million) 

1. Global Irritable Bowel Syndrome (IBS) Treatment Market Share by IBS Type, 2025 Vs 2035 (%) 

2. Global IBS with Constipation (IBS-C) Market Share by Region, 2025 Vs 2035 (%) 

3. Global IBS with Diarrhea (IBS-D) Market Share by Region, 2025 Vs 2035 (%) 

4. Global Mixed IBS (IBS-M) Market Share by Region, 2025 Vs 2035 (%) 

5. Global Unsubtyped IBS (IBS-U) Market Share by Region, 2025 Vs 2035 (%) 

6. Global Irritable Bowel Syndrome (IBS) Treatment Market Share by Drug Class, 2025 Vs 2035 (%) 

7. Global Laxatives Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

8. Global Antidiarrheal Agents Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

9. Global Antispasmodics Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

10. Global Antibiotics Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

11. Global Serotonin Receptor Modulators Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

12. Global Guanylate Cyclase-C Agonists Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

13. Global Chloride Channel Activators Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

14. Global Antidepressants Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

15. Global Bile Acid Sequestrants Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

16. Global Irritable Bowel Syndrome IBS Treatment for Hospitals Market Share by Region, 2025 Vs 2035 (%) 

17. Global Irritable Bowel Syndrome IBS Treatment for Specialty Gastroenterology Clinics Market Share by Region, 2025 Vs 2035 (%) 

18. Global Irritable Bowel Syndrome IBS Treatment for Homecare Settings Market Share by Region, 2025 Vs 2035 (%) 

19. Global Irritable Bowel Syndrome (IBS) Treatment Market Share by Region, 2025 Vs 2035 (%) 

20. United States Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

21. Canada Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

22. UK Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

23. France Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

24. Germany Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

25. Italy Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

26. Spain Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

27. Russia Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

28. India Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

29. China Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

30. Japan Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

31. South Korea Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

32. Australia & New Zealand Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

33. ASEAN Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

34. Rest of Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

35. Latin America Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

36. Middle East & Africa Irritable Bowel Syndrome (IBS) Treatment Market Size, 2025-2035 ($ Million) 

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The size of the Irritable Bowel Syndrome (IBS) Treatment Market in 2025 is estimated to be around $12.4 billion.
United States holds the largest share in the Irritable Bowel Syndrome (IBS) Treatment Market.
Leading players in the Irritable Bowel Syndrome (IBS) Treatment Market Includes AbbVie Inc., Ironwood Pharmaceuticals, Takeda Pharmaceutical Company, Bausch Health Companies Inc., and Allergan (AbbVie)., among others.
The Irritable Bowel Syndrome (IBS) Treatment Market is expected to grow at a CAGR of 5.2% from 2026 to 2035.
Rising prevalence of gastrointestinal disorders, increasing stress and lifestyle-related digestive issues, and growing awareness and diagnosis of IBS are driving the Irritable Bowel Syndrome (IBS) Treatment Market growth.